Situgen Med Overview
SituGen is a medical device startup that has developed a comprehensive system for extracting stem-cell-rich umbilical cord blood. The companys patented SG1040 is a disposable, all-inclusive, non-contaminating collection kit designed to increase the quality of cord blood and the number of stem cells extracted. The novel device is needle-free, preventing the bottleneck effect associated with needles. SituGen is an Israel-based company and part of the Rad-Bynet Group of multinational technology companies.
Cumulative Funding Raised Over Time ($)
—Jan 2006
Latest News
growth-positive
SituGen Ltd. Completes Clinical Trials of Revolutionary Device for Umbilical Cord Blood Collection BioSpace
SituGen Ltd. has announced the completion of clinical trials for its innovative device for collecting umbilical cord blood. The trials showed that the device increased the number of stem cells collected by 81%, significantly improving the quantity and quality of stem cells available for transplantation. FDA approval is expected later this year, with European approval to follow. SituGen plans to manufacture and market the device to cord blood banks worldwide. The company also intends to continue research and development in the stem cell and cord blood fields. SituGen was founded in 2003 and is supported by RAD BioMed as an investor and partner.
CustomersPartners
growth-positive
Israeli device lengthens the stem cell cord that save lives
Israeli start-up BioCord has developed the SituGen system, a novel method for collecting more stem cells from the umbilical cord. The current method of extracting cord blood using a needle limits the amount of blood that can be collected. The SituGen system, which does away with the needle, can collect more than double the amount of blood, allowing for the treatment of more illnesses and potentially saving more lives. BioCord is raising $500,000 in funding to market and produce the SituGen system, in addition to the $500,000 already invested by private investors and the Israeli Chief Scientist. The device will cost around $100 and will be distributed through multinational companies to cord blood banks worldwide.
Customers
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Seed |
| Rounds | 2 |
| Investors | 1 |
Team Members
1
Employees: 1-10
Web & Social Links
| Website | www.situgen.com |
Locations
Ha-Arad Street 7, Tel Aviv-Yafo, Israel
Photos & Videos
3 item(s)
Situgen Med Business
Business models
B2B
Product stage
Released
Employees
1-10
Sector
Health Tech & Life SciencesMedical DevicesMedical Treatment & TherapeuticsTarget Customer
Healthcare & Life SciencesMedical Devices IndustryMedical ProductsCore Technology
—Tags (7)
medical-devicespregnancymedical-technologiesminimally-invasiveblood-testnon-invasivehematologyGeographic Markets
IsraelSitugen Med Financials
Undisclosed
Total funding
Undisclosed
Capital raised
Undisclosed
Last funding
Seed
Funding stage
2
Total rounds
1
Investors
Cumulative Funding Raised Over Time ($)
—Jan 2006
Private Equity Funding
Undisclosed Round
Jan 2006
Undisclosed
RAD BioMed
Non-Equity Funding
GrantEvent
Jan 2006
Undisclosed
Situgen Med Lifecycle
Cumulative Funding Raised Over Time
—Jan 2006
All Events
Undisclosed Round
Jan 2006
Undisclosed
RAD BioMed
GrantEvent
Jan 2006
Undisclosed
Situgen Med News
2 articles
growth-positive
SituGen Ltd. Completes Clinical Trials of Revolutionary Device for Umbilical Cord Blood Collection BioSpace
SituGen Ltd. has announced the completion of clinical trials for its innovative device for collecting umbilical cord blood. The trials showed that the device increased the number of stem cells collected by 81%, significantly improving the quantity and quality of stem cells available for transplantation. FDA approval is expected later this year, with European approval to follow. SituGen plans to manufacture and market the device to cord blood banks worldwide. The company also intends to continue research and development in the stem cell and cord blood fields. SituGen was founded in 2003 and is supported by RAD BioMed as an investor and partner.
CustomersPartners
growth-positive
Israeli device lengthens the stem cell cord that save lives
Israeli start-up BioCord has developed the SituGen system, a novel method for collecting more stem cells from the umbilical cord. The current method of extracting cord blood using a needle limits the amount of blood that can be collected. The SituGen system, which does away with the needle, can collect more than double the amount of blood, allowing for the treatment of more illnesses and potentially saving more lives. BioCord is raising $500,000 in funding to market and produce the SituGen system, in addition to the $500,000 already invested by private investors and the Israeli Chief Scientist. The device will cost around $100 and will be distributed through multinational companies to cord blood banks worldwide.
Customers
Situgen Med Team
Employee Info
| Employees (range) | 1-10 |
| Team members | 1 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 6 classification IDs that could be used for matching.
Situgen Med Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 90/100 |
| Missing | markets, not claimed |
| BI Verification | Yotam Maman |
| Registrar ID | 515380749 |
| Phone | +97236412022 |
| Creator | Matan Eblagon |
| Creator email | matane@sncentral.org |
| Last updater | Matan Eblagon |
| Updater email | matane@sncentral.org |
| Last update | 2022-04-20T00:00:00.000Z |
| Created | 2022-04-20T00:00:00.000Z |